GLP‑1 / Ozempic litigation
Lawsuits allege that the makers of GLP‑1 medications, including Ozempic, Wegovy, Rybelsus, Saxenda, and Mounjaro, failed to warn patients about the risk of severe gastrointestinal injury.
Accepting cases
What the lawsuits allege
GLP‑1 receptor agonists were prescribed to millions of people for type 2 diabetes and weight loss. The litigation alleges that the manufacturers knew these drugs slow gastric emptying far more severely in some patients than the labels disclosed, and that patients were left with long-lasting or permanent stomach paralysis, intractable vomiting, and related complications.
Cases are coordinated in a federal multidistrict litigation. Each claim remains individual: your injuries, your prescriptions, and your medical records determine your case.
Injuries named in the litigation
- Gastroparesis (stomach paralysis)
- Persistent vomiting and cyclic vomiting syndrome
- Bowel obstruction (ileus)
- NAION vision loss
- Gallbladder disease and removal
Who may qualify
If you used Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro, or another GLP‑1 medication and were diagnosed with gastroparesis, a bowel obstruction, NAION vision loss, or required hospitalization for severe gastrointestinal injury, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.